Table 1.
Pathohistological data and INK4a-ARF alterations
p14 alterations | p16 alterations | ||||||||
Patient No | Sex (M/F) | Tumour size diameter (cm) | RE-PCR | MSP | EXP | RE-PCR | MSP | EXP | Allelic status |
1 | F | 2.5 | — | — | +++ | +++ | +++ | — | ND |
2 | F | 4.9 | — | — | +++ | — | — | +++ | ND |
3 | F | 10.5 | — | — | +++ | — | — | +++ | ND |
4 | M | 5.5 | — | — | +++ | — | — | +++ | ND |
5 | F | 6.5 | — | — | +++ | — | — | +++ | ND |
6 | F | 3.0 | — | — | +++ | — | — | +++ | ND |
7 | F | 12.5 | — | — | +++ | — | — | +++ | ND |
8 | F | 7.6 | — | — | +++ | — | — | +++ | ND |
9 | M | 8.0 | — | — | +++ | — | — | +++ | NI |
10 | F | 8.5 | — | — | +++ | — | — | +++ | ND |
11 | F | 10.8 | +++ | +++ | — | — | — | +++ | ND |
12 | F | 4.5 | — | — | +++ | — | — | +++ | ND |
13 | F | 14.0 | — | — | +++ | — | — | +++ | NI |
14 | F | 10.5 | — | — | +++ | — | — | +++ | ND |
15 | F | 9.5 | — | — | +++ | — | — | +++ | ND |
16 | F | 8.2 | +++ | +++ | — | — | — | +++ | ND |
17 | F | 7.5 | — | — | +++ | — | — | +++ | ND |
18 | F | 9.6 | — | — | +++ | +++ | +++ | — | ND |
19 | M | 8.3 | — | — | +++ | — | — | +++ | ND |
20 | F | 7.8 | — | — | +++ | — | — | +++ | ND |
21 | F | 3.9 | — | — | +++ | +++ | +++ | — | ND |
22 | F | 9.0 | — | — | +++ | +++ | +++ | — | ND |
23 | F | 6.5 | — | — | +++ | +++ | +++ | — | ND |
24 | F | 10.2 | +++ | +++ | — | — | — | +++ | ND |
25 | F | 7.8 | — | — | +++ | +++ | +++ | — | ND |
RE-PCR, restriction enzyme related-polymerase chain reaction; MSP, methylation specific PCR; EXP, gene mRNA expression analysed by reverse transcription PCR; ND, not detected (wild-type, both allels expressed as defined by multiplex PCR); NI, not informative.